id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0201-0006,FDA,FDA-2004-E-0201,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-09-08T04:00:00Z,2006,9,,,2025-11-20T20:26:20Z,,0,0,0900006480470be5
FDA-2004-E-0201-0005,FDA,FDA-2004-E-0201,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-19T04:00:00Z,2006,6,,,2025-11-20T20:24:41Z,,0,0,0900006480470be4
FDA-2004-E-0201-0004,FDA,FDA-2004-E-0201,Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,General Notice,2006-02-02T05:00:00Z,2006,2,2006-01-31T05:00:00Z,2006-04-04T03:59:59Z,2025-11-20T20:20:10Z,,0,0,0900006480470be2
FDA-2004-E-0201-0003,FDA,FDA-2004-E-0201,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-01-11T05:00:00Z,2006,1,,,2025-11-20T20:16:03Z,,0,0,0900006480470be1